Evidence-Based Prescription Drug Program
- Providing High Quality Care
- Controlling Costs to Avoid Cuts in Services or Reimbursements
- Avoid Care Delivery Hassles
Those are the goals for most healthcare providers. They are also the driving forces guiding development of the Arkansas Medicaid Preferred Drug List (PDL). The Evidence-based Prescription Drug Program (EBRx) was created to ensure that Arkansas’ Medicaid PDL provides access to medications which provide clinical advantages and the opportunity to control costs.
Over the past eight years, Arkansas Medicaid prescription spending has grown at an average annual rate of 16 percent. Unfortunately, average prescription costs continue to rise. As the state’s budget is finite, the current prescription cost growth is unsustainable. The challenge facing EBRx is ensuring access to medications proven most effective and safe while providing cost control.